The book explores cutting-edge strategies to overcome proteasome
inhibitor resistance, including the second generation 20S
proteasome inhibitors, novel combinational therapies, and new
targets in the ubiquitin-proteasome pathway (e.g., ubiquitin E3
ligases, deubiquitinases, 19S proteasomal ATPases, histone
deacetylases, oxidative stress and proteotoxic stress pathways and
pharmacogenomic signature profiling) in resistant cancer cells. The
mechanisms of action and resistance of proteasome inhibitors, such
as bortezomib and carfilzomib in human cancers, including multiple
myeloma, mantle cell lymphoma, acute leukemia, and solid tumors are
explored in depth in this volume.
This timely volume unveils the most current discoveries of the
mechanisms behind proteasome inhibitor resistance, which will help
illuminate the future of cancer therapies.
General
Is the information for this product incomplete, wrong or inappropriate?
Let us know about it.
Does this product have an incorrect or missing image?
Send us a new image.
Is this product missing categories?
Add more categories.
Review This Product
No reviews yet - be the first to create one!